Rational design of MyD88 inhibitors - New pathways to inflammatory control: An interview with Dr. Claudio Sette

Journal of Leukocyte Biology

Volumn 82, Issue 4, 2007, Pages 811-812

  Rosenberg, Helene F ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOID DIFFERENTIATION FACTOR 88; PEPTIDE DERIVATIVE; ST 2825; UNCLASSIFIED DRUG;

DIMERIZATION; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; INFLAMMATION; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOMIMETIC MATERIALS; DRUG DESIGN; HUMANS; MICE; MODELS, MOLECULAR; MYELOID DIFFERENTIATION FACTOR 88; OLIGOPEPTIDES; PORTRAITS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 9;

EID: 34848860452     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.1306746     Document Type: Note

References (4)

1. Loiarro, M., Sette, C., Gallo, G., Ciacci, A., Fantò, N., Mastroianni, D., Carminati, P., Ruggiero, V. (2005) Peptide-mediated Interference of TIR Domain Dimerization in MyD88 Inhibits Interleukin-1- dependent Activation of NF-kB. J. Biol. Chem. 280, 15809-15814.
2. Bartfai, T., Behrens, M. M., Gaidarova, S., Pemberton, J., Shivanyuk, A., Rebek, J., Jr. (2003) A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc. Natl. Acad. Sci. USA 100, 7971-7976.
3. Prinz, M., Garbe, F., Schmidt, H., Mildner A, Gutcher, I., Wolter, K., Piesche, M., Schroers, R., Weiss, E., Kirschning, C. J., Rochford, C. D., Brück, W., Becher, B. (2006) Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 116, 456-464.
4. Steinman, L., Zamvil, S. S. (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60, 12-21.